Oramed Pharmaceuticals Enters Material Definitive Agreement
Ticker: ORMP · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
Oramed signed a big deal, details TBD.
AI Summary
Oramed Pharmaceuticals Inc. announced on February 22, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated dollar amounts. The company is incorporated in Delaware and its principal executive offices are located in New York.
Why It Matters
This filing indicates a significant business development for Oramed Pharmaceuticals, potentially impacting its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- February 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive offices location
FAQ
What is the nature of the material definitive agreement entered into by Oramed Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
When did Oramed Pharmaceuticals enter into this material definitive agreement?
The earliest event reported in the filing is February 22, 2025.
Are there any financial terms disclosed for this agreement?
No specific dollar amounts or financial terms are disclosed in this filing.
Where is Oramed Pharmaceuticals Inc. incorporated?
Oramed Pharmaceuticals Inc. is incorporated in Delaware.
What is the business address of Oramed Pharmaceuticals Inc.?
The business address is 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding ORAMED PHARMACEUTICALS INC. (ORMP).